APO Research
Talk to an analyst

APO RESEARCH · REPORT

PCSK9 Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PCSK9 Antagonists Market Outlook and Growth Opportunities 2026

29 December 2025193 pages

Choose your research edition.

Industry ResearchPCSK9 Antagonists Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal PCSK9 Antagonists Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal PCSK9 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PCSK9 Antagonists Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PCSK9 Antagonists Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global PCSK9 Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PCSK9 Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PCSK9 Antagonists market include Amgen, Merck, Novartis, Regeneron Pharmaceuticals, Sanofi, Hasten Biopharmaceutical, Jiangsu Hengrui Pharmaceuticals, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PCSK9 Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PCSK9 Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PCSK9 Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PCSK9 Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

PCSK9 Antagonists Segment by Company

Amgen

Merck

Novartis

Regeneron Pharmaceuticals

Sanofi

Hasten Biopharmaceutical

Jiangsu Hengrui Pharmaceuticals

Junshi Biosciences

Akeso

Innovent Biologics

Salubris Pharmaceuticals

PCSK9 Antagonists Segment by Type

Monoclonal Antibody

siRNA

Other

PCSK9 Antagonists Segment by Application

Atherosclerotic Cardiovascular Disease

Hypercholesterolemia

Others

PCSK9 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PCSK9 Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PCSK9 Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PCSK9 Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze PCSK9 Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PCSK9 Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PCSK9 Antagonists industry.

Chapter 3: Detailed analysis of PCSK9 Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PCSK9 Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PCSK9 Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PCSK9 Antagonists Industry Trends Table 2. PCSK9 Antagonists Industry Drivers Table 3. PCSK9 Antagonists Industry Opportunities and Challenges Table 4. PCSK9 Antagonists Industry Restraints Table 5. Global PCSK9 Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PCSK9 Antagonists Revenue Share by Company (2021-2026) Table 7. Global PCSK9 Antagonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global PCSK9 Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global PCSK9 Antagonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global PCSK9 Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global PCSK9 Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global PCSK9 Antagonists Company, Product Type & Application Table 13. Global PCSK9 Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PCSK9 Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monoclonal Antibody Table 18. Significant Companies of siRNA Table 19. Significant Companies of Other Table 20. Global PCSK9 Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global PCSK9 Antagonists Sales Volume by Type (2021-2026) & (K Units) Table 22. Global PCSK9 Antagonists Sales Volume by Type (2027-2032) & (K Units) Table 23. Global PCSK9 Antagonists Sales Volume Share by Type (2021-2026) Table 24. Global PCSK9 Antagonists Sales Volume Share by Type (2027-2032) Table 25. Global PCSK9 Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global PCSK9 Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global PCSK9 Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global PCSK9 Antagonists Sales Value Share by Type (2021-2026) Table 29. Global PCSK9 Antagonists Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Atherosclerotic Cardiovascular Disease Table 31. Significant Companies of Hypercholesterolemia Table 32. Significant Companies of Others Table 33. Global PCSK9 Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global PCSK9 Antagonists Sales Volume by Application (2021-2026) & (K Units) Table 35. Global PCSK9 Antagonists Sales Volume by Application (2027-2032) & (K Units) Table 36. Global PCSK9 Antagonists Sales Volume Share by Application (2021-2026) Table 37. Global PCSK9 Antagonists Sales Volume Share by Application (2027-2032) Table 38. Global PCSK9 Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global PCSK9 Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global PCSK9 Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global PCSK9 Antagonists Sales Value Share by Application (2021-2026) Table 42. Global PCSK9 Antagonists Sales Value Share by Application (2027-2032) Table 43. Global PCSK9 Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global PCSK9 Antagonists Sales by Region (2021-2026) & (K Units) Table 45. Global PCSK9 Antagonists Sales Market Share by Region (2021-2026) Table 46. Global PCSK9 Antagonists Sales by Region (2027-2032) & (K Units) Table 47. Global PCSK9 Antagonists Sales Market Share by Region (2027-2032) Table 48. Global PCSK9 Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global PCSK9 Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global PCSK9 Antagonists Sales Value Share by Region (2021-2026) Table 51. Global PCSK9 Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global PCSK9 Antagonists Sales Value Share by Region (2027-2032) Table 53. Global PCSK9 Antagonists Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global PCSK9 Antagonists Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global PCSK9 Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global PCSK9 Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 58. Global PCSK9 Antagonists Sales Market Share by Country (2021-2026) Table 59. Global PCSK9 Antagonists Sales by Country (2027-2032) & (K Units) Table 60. Global PCSK9 Antagonists Sales Market Share by Country (2027-2032) Table 61. Global PCSK9 Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global PCSK9 Antagonists Sales Value Market Share by Country (2021-2026) Table 63. Global PCSK9 Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global PCSK9 Antagonists Sales Value Market Share by Country (2027-2032) Table 65. Amgen Company Information Table 66. Amgen Business Overview Table 67. Amgen PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Amgen PCSK9 Antagonists Product Portfolio Table 69. Amgen Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Merck PCSK9 Antagonists Product Portfolio Table 74. Merck Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Novartis PCSK9 Antagonists Product Portfolio Table 79. Novartis Recent Development Table 80. Regeneron Pharmaceuticals Company Information Table 81. Regeneron Pharmaceuticals Business Overview Table 82. Regeneron Pharmaceuticals PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Regeneron Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 84. Regeneron Pharmaceuticals Recent Development Table 85. Sanofi Company Information Table 86. Sanofi Business Overview Table 87. Sanofi PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sanofi PCSK9 Antagonists Product Portfolio Table 89. Sanofi Recent Development Table 90. Hasten Biopharmaceutical Company Information Table 91. Hasten Biopharmaceutical Business Overview Table 92. Hasten Biopharmaceutical PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Hasten Biopharmaceutical PCSK9 Antagonists Product Portfolio Table 94. Hasten Biopharmaceutical Recent Development Table 95. Jiangsu Hengrui Pharmaceuticals Company Information Table 96. Jiangsu Hengrui Pharmaceuticals Business Overview Table 97. Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 99. Jiangsu Hengrui Pharmaceuticals Recent Development Table 100. Junshi Biosciences Company Information Table 101. Junshi Biosciences Business Overview Table 102. Junshi Biosciences PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Junshi Biosciences PCSK9 Antagonists Product Portfolio Table 104. Junshi Biosciences Recent Development Table 105. Akeso Company Information Table 106. Akeso Business Overview Table 107. Akeso PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Akeso PCSK9 Antagonists Product Portfolio Table 109. Akeso Recent Development Table 110. Innovent Biologics Company Information Table 111. Innovent Biologics Business Overview Table 112. Innovent Biologics PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Innovent Biologics PCSK9 Antagonists Product Portfolio Table 114. Innovent Biologics Recent Development Table 115. Salubris Pharmaceuticals Company Information Table 116. Salubris Pharmaceuticals Business Overview Table 117. Salubris Pharmaceuticals PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Salubris Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 119. Salubris Pharmaceuticals Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. PCSK9 Antagonists Distributors List Table 123. PCSK9 Antagonists Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. PCSK9 Antagonists Product Image Figure 2. Global PCSK9 Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PCSK9 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global PCSK9 Antagonists Sales (2021-2032) & (K Units) Figure 5. Global PCSK9 Antagonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global PCSK9 Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monoclonal Antibody Image Figure 10. siRNA Image Figure 11. Other Image Figure 12. Global PCSK9 Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global PCSK9 Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global PCSK9 Antagonists Sales Volume Share by Type (2021-2032) Figure 15. Global PCSK9 Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global PCSK9 Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global PCSK9 Antagonists Sales Value Share by Type (2021-2032) Figure 18. Atherosclerotic Cardiovascular Disease Image Figure 19. Hypercholesterolemia Image Figure 20. Others Image Figure 21. Global PCSK9 Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global PCSK9 Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global PCSK9 Antagonists Sales Volume Share by Application (2021-2032) Figure 24. Global PCSK9 Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global PCSK9 Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global PCSK9 Antagonists Sales Value Share by Application (2021-2032) Figure 27. Global PCSK9 Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global PCSK9 Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global PCSK9 Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global PCSK9 Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America PCSK9 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 32. North America PCSK9 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe PCSK9 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 34. Europe PCSK9 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific PCSK9 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific PCSK9 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America PCSK9 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 38. South America PCSK9 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa PCSK9 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa PCSK9 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt PCSK9 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. PCSK9 Antagonists Value Chain Figure 126. Manufacturing Cost Structure Figure 127. PCSK9 Antagonists Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • siRNA
  • Other
Applications
  • Atherosclerotic Cardiovascular Disease
  • Hypercholesterolemia
  • Others
Companies covered
  • Amgen
  • Merck
  • Novartis
  • Regeneron Pharmaceuticals
  • Sanofi
  • Hasten Biopharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Junshi Biosciences
  • Akeso
  • Innovent Biologics
  • Salubris Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PCSK9 Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global PCSK9 Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global PCSK9 Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PCSK9 Antagonists Market Dynamics
  1. 2.1 PCSK9 Antagonists Industry Trends
  2. 2.2 PCSK9 Antagonists Industry Drivers
  3. 2.3 PCSK9 Antagonists Industry Opportunities and Challenges
  4. 2.4 PCSK9 Antagonists Industry Restraints
3 PCSK9 Antagonists Market by Company
  1. 3.1 Global PCSK9 Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global PCSK9 Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global PCSK9 Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global PCSK9 Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global PCSK9 Antagonists Company Ranking (2024-2026)
  6. 3.6 Global PCSK9 Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global PCSK9 Antagonists Company Product Type and Application
  8. 3.8 Global PCSK9 Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PCSK9 Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PCSK9 Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PCSK9 Antagonists Market by Type
  1. 4.1 PCSK9 Antagonists Type Introduction
  2. 4.1.1 Monoclonal Antibody
  3. 4.1.2 siRNA
  4. 4.1.3 Other
  5. 4.2 Global PCSK9 Antagonists Sales Volume by Type
  6. 4.2.1 Global PCSK9 Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PCSK9 Antagonists Sales Volume by Type (2021-2032)
  8. 4.2.3 Global PCSK9 Antagonists Sales Volume Share by Type (2021-2032)
  9. 4.3 Global PCSK9 Antagonists Sales Value by Type
  10. 4.3.1 Global PCSK9 Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global PCSK9 Antagonists Sales Value by Type (2021-2032)
  12. 4.3.3 Global PCSK9 Antagonists Sales Value Share by Type (2021-2032)
5 PCSK9 Antagonists Market by Application
  1. 5.1 PCSK9 Antagonists Application Introduction
  2. 5.1.1 Atherosclerotic Cardiovascular Disease
  3. 5.1.2 Hypercholesterolemia
  4. 5.1.3 Others
  5. 5.2 Global PCSK9 Antagonists Sales Volume by Application
  6. 5.2.1 Global PCSK9 Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PCSK9 Antagonists Sales Volume by Application (2021-2032)
  8. 5.2.3 Global PCSK9 Antagonists Sales Volume Share by Application (2021-2032)
  9. 5.3 Global PCSK9 Antagonists Sales Value by Application
  10. 5.3.1 Global PCSK9 Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PCSK9 Antagonists Sales Value by Application (2021-2032)
  12. 5.3.3 Global PCSK9 Antagonists Sales Value Share by Application (2021-2032)
6 PCSK9 Antagonists Regional Sales and Value Analysis
  1. 6.1 Global PCSK9 Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PCSK9 Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global PCSK9 Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global PCSK9 Antagonists Sales by Region (2027-2032)
  5. 6.3 Global PCSK9 Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PCSK9 Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global PCSK9 Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global PCSK9 Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global PCSK9 Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PCSK9 Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America PCSK9 Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PCSK9 Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe PCSK9 Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PCSK9 Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PCSK9 Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PCSK9 Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America PCSK9 Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PCSK9 Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PCSK9 Antagonists Sales Value Share by Country, 2025 VS 2032
7 PCSK9 Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global PCSK9 Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PCSK9 Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PCSK9 Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global PCSK9 Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global PCSK9 Antagonists Sales by Country (2027-2032)
  6. 7.4 Global PCSK9 Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global PCSK9 Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global PCSK9 Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PCSK9 Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PCSK9 Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PCSK9 Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen PCSK9 Antagonists Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck PCSK9 Antagonists Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis PCSK9 Antagonists Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals PCSK9 Antagonists Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi PCSK9 Antagonists Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Hasten Biopharmaceutical
  32. 8.6.1 Hasten Biopharmaceutical Company Information
  33. 8.6.2 Hasten Biopharmaceutical Business Overview
  34. 8.6.3 Hasten Biopharmaceutical PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hasten Biopharmaceutical PCSK9 Antagonists Product Portfolio
  36. 8.6.5 Hasten Biopharmaceutical Recent Developments
  37. 8.7 Jiangsu Hengrui Pharmaceuticals
  38. 8.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
  39. 8.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  40. 8.7.3 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Product Portfolio
  42. 8.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  43. 8.8 Junshi Biosciences
  44. 8.8.1 Junshi Biosciences Company Information
  45. 8.8.2 Junshi Biosciences Business Overview
  46. 8.8.3 Junshi Biosciences PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Junshi Biosciences PCSK9 Antagonists Product Portfolio
  48. 8.8.5 Junshi Biosciences Recent Developments
  49. 8.9 Akeso
  50. 8.9.1 Akeso Company Information
  51. 8.9.2 Akeso Business Overview
  52. 8.9.3 Akeso PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Akeso PCSK9 Antagonists Product Portfolio
  54. 8.9.5 Akeso Recent Developments
  55. 8.10 Innovent Biologics
  56. 8.10.1 Innovent Biologics Company Information
  57. 8.10.2 Innovent Biologics Business Overview
  58. 8.10.3 Innovent Biologics PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Innovent Biologics PCSK9 Antagonists Product Portfolio
  60. 8.10.5 Innovent Biologics Recent Developments
  61. 8.11 Salubris Pharmaceuticals
  62. 8.11.1 Salubris Pharmaceuticals Company Information
  63. 8.11.2 Salubris Pharmaceuticals Business Overview
  64. 8.11.3 Salubris Pharmaceuticals PCSK9 Antagonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Salubris Pharmaceuticals PCSK9 Antagonists Product Portfolio
  66. 8.11.5 Salubris Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PCSK9 Antagonists Value Chain Analysis
  2. 9.1.1 PCSK9 Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PCSK9 Antagonists Sales Mode & Process
  6. 9.2 PCSK9 Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PCSK9 Antagonists Distributors
  9. 9.2.3 PCSK9 Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst